Eli Lilly & Co (1LLY) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1LLY Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1LLY Stock 12 Month Forecast

Average Price Target

€771.93

▲(25.42% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €771.93 with a high forecast of €1,015.09 and a low forecast of €597.11. The average price target represents a 25.42% change from the last price of €615.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"596":"€596","701":"€701","806":"€806","911":"€911","1016":"€1,016"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1015.0941927,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":771.9322174302,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€771.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":597.114231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€597.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[596,701,806,911,1016],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,619.3,649.7457071307692,680.1914142615384,710.6371213923077,741.0828285230768,771.5285356538461,801.9742427846154,832.4199499153847,862.8656570461538,893.311364176923,923.7570713076923,954.2027784384616,984.6484855692308,{"y":1015.0941927,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,619.3,631.040939802323,642.7818796046461,654.5228194069692,666.2637592092923,678.0046990116153,689.7456388139384,701.4865786162616,713.2275184185846,724.9684582209077,736.7093980232307,748.4503378255538,760.191277627877,{"y":771.9322174302,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,619.3,617.5934023846154,615.8868047692307,614.1802071538461,612.4736095384615,610.7670119230769,609.0604143076923,607.3538166923076,605.6472190769231,603.9406214615385,602.2340238461538,600.5274262307693,598.8208286153846,{"y":597.114231,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":860.397,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":792.327,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":753.529,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":756.178,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":758.662,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.896,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":860.429,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":753.896,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":784.562,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":647.708,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":667.961,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":654.991,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":619.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1,015

Average Price Target€771.93

Lowest Price Target€597.11

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

CFRA

Not Ranked

CFRA

€715.62

Buy

16.27%

Upside

Upgraded

09/26/25

Positive Report for Eli Lilly & Co (LLY) from CFRA

Veda Pharmyne

TR | OpenAI - 4o

€710.48→€713.91

Buy

15.99%

Upside

Reiterated

09/24/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

€942.73

Buy

53.17%

Upside

Assigned

09/23/25

Eli Lilly & Co's Promising Growth Prospects Reinforced by Orfo Study Success and Strategic Patient-Centric Approach

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

09/22/25

Eli Lilly & Co: Strong Market Position and Growth Potential Drive Buy Rating

David Risinger

Leerink Partners

―

Hold

―

Reiterated

09/18/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Tim Anderson

Bank of America Securities

―

Buy

―

Reiterated

09/18/25

Bank of America Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Mohit Bansal

Wells Fargo

€942.73

Buy

53.17%

Upside

Reiterated

09/18/25

Wells Fargo Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

€719.9

Buy

16.96%

Upside

Reiterated

09/18/25

Eli Lilly & Co: Promising Future Backed by Strong Pipeline and Positive Study Results

Carter Gould

Cantor Fitzgerald

€707.05

Buy

14.87%

Upside

Reiterated

09/17/25

Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Geoff Meacham

Citi

€1,019.87

Buy

65.70%

Upside

Reiterated

09/17/25

Citi Remains a Buy on Eli Lilly & Co (LLY)

Kerry Holford

Berenberg Bank

€711.33

Hold

15.57%

Upside

Downgraded

09/16/25

Eli Lilly & Co: Hold Rating Amid Competitive Pressures and Valuation Concerns

Trung Huynh

UBS

€767.04

Buy

24.62%

Upside

Reiterated

08/27/25

UBS Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Rajesh Kumar

HSBC

€599.92

Hold

-2.53%

Downside

Upgraded

08/27/25

Eli Lilly upgraded to Hold from Reduce at HSBCEli Lilly upgraded to Hold from Reduce at HSBC

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

€749.9

Buy

21.84%

Upside

Reiterated

08/26/25

Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

CFRA

Not Ranked

CFRA

€715.62

Buy

16.27%

Upside

Upgraded

09/26/25

Positive Report for Eli Lilly & Co (LLY) from CFRA

Veda Pharmyne

TR | OpenAI - 4o

€710.48→€713.91

Buy

15.99%

Upside

Reiterated

09/24/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

€942.73

Buy

53.17%

Upside

Assigned

09/23/25

Eli Lilly & Co's Promising Growth Prospects Reinforced by Orfo Study Success and Strategic Patient-Centric Approach

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

09/22/25

Eli Lilly & Co: Strong Market Position and Growth Potential Drive Buy Rating

David Risinger

Leerink Partners

―

Hold

―

Reiterated

09/18/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Tim Anderson

Bank of America Securities

―

Buy

―

Reiterated

09/18/25

Bank of America Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Mohit Bansal

Wells Fargo

€942.73

Buy

53.17%

Upside

Reiterated

09/18/25

Wells Fargo Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

€719.9

Buy

16.96%

Upside

Reiterated

09/18/25

Eli Lilly & Co: Promising Future Backed by Strong Pipeline and Positive Study Results

Carter Gould

Cantor Fitzgerald

€707.05

Buy

14.87%

Upside

Reiterated

09/17/25

Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Geoff Meacham

Citi

€1,019.87

Buy

65.70%

Upside

Reiterated

09/17/25

Citi Remains a Buy on Eli Lilly & Co (LLY)

Kerry Holford

Berenberg Bank

€711.33

Hold

15.57%

Upside

Downgraded

09/16/25

Eli Lilly & Co: Hold Rating Amid Competitive Pressures and Valuation Concerns

Trung Huynh

UBS

€767.04

Buy

24.62%

Upside

Reiterated

08/27/25

UBS Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Rajesh Kumar

HSBC

€599.92

Hold

-2.53%

Downside

Upgraded

08/27/25

Eli Lilly upgraded to Hold from Reduce at HSBCEli Lilly upgraded to Hold from Reduce at HSBC

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

€749.9

Buy

21.84%

Upside

Reiterated

08/26/25

Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

31/43 ratings generated profit

Average Return

+4.60%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.09% of your transactions generating a profit, with an average return of +4.60% per trade.

3 Months

xxx

Success Rate

31/43 ratings generated profit

Average Return

+10.50%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.09% of your transactions generating a profit, with an average return of +10.50% per trade.

1 Year

Geoff MeachamCiti

Success Rate

36/43 ratings generated profit

Average Return

+32.84%

reiterated a buy rating 12 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 83.72% of your transactions generating a profit, with an average return of +32.84% per trade.

2 Years

xxx

Success Rate

28/33 ratings generated profit

Average Return

+27.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.85% of your transactions generating a profit, with an average return of +27.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1LLY Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1LLY has received 71 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. 1LLY average Analyst price target in the past 3 months is 771.93.

Each month's total comprises the sum of three months' worth of ratings.

1LLY Financial Forecast

1LLY Earnings Forecast

Next quarter’s earnings estimate for 1LLY is €5.42 with a range of €4.79 to €6.41. The previous quarter’s EPS was €5.38. 1LLY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 1LLY has Preformed in-line its overall industry.

1LLY Sales Forecast

Next quarter’s sales forecast for 1LLY is €13.68B with a range of €13.14B to €14.01B. The previous quarter’s sales results were €13.27B. 1LLY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 1LLY has Preformed in-line its overall industry.

1LLY Stock Forecast FAQ

What is IT:1LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 771.93.

What is IT:1LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly And Company has 25.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly And Company a Buy, Sell or Hold?

Eli Lilly And Company has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Eli Lilly And Company’s share price target?

The average share price target for Eli Lilly And Company is 771.93. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,015.09 ,and the lowest forecast is €597.11. The average share price target represents 25.42% Increase from the current price of €615.5.

What do analysts say about Eli Lilly And Company?

Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Eli Lilly And Company?

To buy shares of IT:1LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eli Lilly & Co (1LLY) Stock Forecast & Price Target

1LLY Analyst Ratings

1LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

1LLY Analyst Recommendation Trends

1LLY Financial Forecast

1LLY Earnings Forecast

1LLY Sales Forecast

1LLY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts